Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 13
Submit an article Journal homepage
147
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma

Izidore S. Lossosa Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA;b Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence[email protected]
,
Isildinha M. Reisc Department of Public Health Science, University of Miami Miller School of Medicine, Miami, FL, USA;d Biostatistics and Bioinformatics Core Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
,
Joseph D. Rosenblatta Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA
&
Juan Pablo Alderuccioa Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA
Pages 3234-3238 | Received 14 May 2020, Accepted 15 Jul 2020, Published online: 05 Aug 2020

References

  • Alderuccio JP, Isrow D, Reis IM, et al. Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not? Blood. 2020;135(15):1299–1302.
  • Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905–1912.
  • Salar A, Domingo-Domenech E, Panizo C, et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;130(15):1772–1774.
  • Becnel MR, Nastoupil LJ, Samaniego F, et al. Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019;185(5):874–882.
  • Lossos IS, Morgensztern D, Blaya M, et al. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma. Leuk Lymphoma. 2007;48(8):1630–1632.
  • Lolli G, Argnani L, Broccoli A, et al. 90 Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) – The Zeno Study. Br J Haematol. 2020;189(1):e6–e9.
  • Illidge TM, McKenzie HS, Mayes S, et al. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Br J Haematol. 2016;173(2):274–282.
  • Sachpekidis C, Jackson DB, Soldatos TG. Radioimmunotherapy in Non-Hodgkin’s lymphoma: retrospective adverse event profiling of Zevalin and Bexxar. Pharmaceuticals. 2019;12:141.
  • Lossos IS, Fabregas JC, Koru-Sengul T, et al. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Leuk Lymphoma. 2015;56(6):1750–1755.
  • Esmaeli B, McLaughlin P, Pro B, et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009;20(4):709–714.
  • Zinzani PL, Tani M, Fanti S, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer. 2008;112(4):856–862.
  • Hoffmann M, Troch M, Eidherr H, et al. 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma. Leuk Lymphoma. 2011;52(1):42–45.
  • Vanazzi A, Grana C, Crosta C, et al. Efficacy of 90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. Hematol Oncol. 2014;32(1):10–15.
  • Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25(27):4285–4292.
  • Samaniego F, Berkova Z, Romaguera JE, et al. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014;167(2):207–213.
  • Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47(4):629–636.
  • Gordon LI, Witzig T, Molina A, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma. 2004;5(2):98–101.
  • Olszewski AJ, Reagan JL, Castillo JJ. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. Am J Hematol. 2018;93(1):E1–E3.
  • Penne M, Sarraf Yazdy M, Nair KS, et al. Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies. Clin Lymphoma Myeloma Leuk. 2017;17(10):637–644.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.